Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: a case report.
Hiroaki IijimaAkihiro SakaiKoji EbisumotoMayu YamauchiTakanobu TeramuraAritomo YamazakiToshihide InagiKenji OkamiPublished in: Journal of medical case reports (2023)
The study presents the first reported case of type 1 diabetes in a patient with head and neck squamous cell carcinoma treated with pembrolizumab monotherapy, in Japan. Efficient interdepartmental collaboration will promote the management of severe immune-related adverse events and improve the quality of life of patients.
Keyphrases
- type diabetes
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- squamous cell carcinoma
- combination therapy
- small cell lung cancer
- advanced non small cell lung cancer
- prognostic factors
- open label
- case report
- randomized controlled trial
- drug induced
- patient reported outcomes
- early onset
- metabolic syndrome
- patient reported
- weight loss
- smoking cessation
- epidermal growth factor receptor